by | Jun 14, 2024 | Publications
Am J Hematol. 2024 Jun 14. doi: 10.1002/ajh.27419. Online ahead of print. ABSTRACT Multiple myeloma (MM) is a heterogeneous and complex disease, both in mutational biology as well as in the clinical presentation of patients. While tailored and biomarker-targeted...
by | Jun 14, 2024 | Publications
Int J Cancer. 2024 Jun 14. doi: 10.1002/ijc.35057. Online ahead of print. ABSTRACT Multiple myeloma (MM) is a heterogeneous disease with a small subset of high-risk patients having poor prognoses. Identifying these patients is crucial for treatment management and...
by | Jun 14, 2024 | Publications
Clin Chem Lab Med. 2024 Jun 17. doi: 10.1515/cclm-2024-0306. Online ahead of print. ABSTRACT OBJECTIVES: Minimal residual disease (MRD) status in multiple myeloma (MM) is an important prognostic biomarker. Personalized blood-based targeted mass spectrometry detecting...
by | Jun 14, 2024 | Publications
Hematol Oncol. 2024 Jul;42(4):e3293. doi: 10.1002/hon.3293. ABSTRACT Current treatment guidelines of myeloma cast nephropathy (MCN) recommend the institution of plasma cell-directed therapy and consideration of therapeutic plasma exchange (TPE), with the goal of rapid...
by | Jun 14, 2024 | Publications
J Bone Oncol. 2024 May 22;46:100609. doi: 10.1016/j.jbo.2024.100609. eCollection 2024 Jun. ABSTRACT Obesity contributes to many cancers, including breast cancer and multiple myeloma, two cancers that often colonize the bone marrow (BM). Obesity often causes metabolic...
by | Jun 14, 2024 | Publications
Clin Lymphoma Myeloma Leuk. 2024 May 15:S2152-2650(24)00174-5. doi: 10.1016/j.clml.2024.05.003. Online ahead of print. ABSTRACT BACKGROUND: Talquetamab is a bispecific antibody targeting the multiple myeloma-associated antigen G protein-coupled receptor family C group...
